January 27, 2023
Congratulations to T32 Fellow, Dr. Chenyu Lin for his recent publications
1/27/2023
- Leveraging Natural Killer Cell Innate Immunity against Hematologic Malignancies: From Stem Cell Transplant to Adoptive Transfer and Beyond. PMID: 36613644
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820370/
- A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host Disease: SYK Inhibition in Chronic GVHD. PMID: 36577483
https://pubmed.ncbi.nlm.nih.gov/36577483/
- Combinatorial Efficacy and Toxicity of an Engineered Toxin Body MT-3724 with Gemcitabine and Oxaliplatin in Relapsed or Refractory Diffuse Large B Cell Lymphoma. https://www.tandfonline.com/doi/full/10.1080/07357907.2022.2162073
- Health-Related Quality of Life Following Allogeneic Hematopoietic Cell Transplantation with Omidubicel Versus Umbilical Cord Blood. Transplantation and Cellular Therapy, 28 September 2022. PMID: 36179986 PMCID: PMC9825638
https://www.sciencedirect.com/science/article/abs/pii/S2666636722016554?via%3Dihub;
https://pubmed.ncbi.nlm.nih.gov/36179986/
November 17, 2022
Grant Writing Tips with Dr Mokrova
Date: 10/5/2022
Health-Related Quality of Life Following Allogeneic Hematopoietic Cell Transplantation with Omidubicel Versus Umbilical Cord Blood
Date: 3/4/2022
The Sickle Cell Disease Functional Assessment (SCD-FA) tool: a feasibility pilot study
